Chiron/Ciba-Geigy vaccine joint venture's Italian subsidiary Sclavo, SpA, has had its establishment license revoked, FDA says in Dec. 20 Federal Register. Biocine acquired Sclavo in 1991 and in October 1992 withdrew all of its products from the U.S., citing unapproved manufacturing changes ("The Pink Sheet" Nov. 9, 1992, T&G-9). The Federal Register notice states that, following inspections of Sclavo by FDA in September and December 1992, FDA notified Sclavo of its intent to revoke the ELA. In a June response, Biocine requested that the ELA be withdrawn. FDA revoked the ELA effective July 27. Sclavo's U.S. business was small, with sales of less than $1 mil. compared to Italian sales of about $ 50 mil. The company was licensed to produce diphtheria, tetanus and pertussis toxoids in various combinations, tuberculin and cholera vaccine
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth